Balance Sheet

Cash Flow Statement

Acquisitions Amortization of Deferred Charges Amortization of Deferred Charges Amortizatization of Intangibles Amortizatization of Intangibles Capital Expenditures Capital Expenditures Cash from Discontinued Operations Cash from Discontinued Operations Cash from Financing Activities Cash from Financing Activities Cash from Investing Activities Cash from Investing Activities Cash from Operations Cash from Operations Change in Account Payables Change in Account Payables Change in Accured Expenses Change in Accured Expenses Change in Acquisitions & Divestments Change in Acquisitions & Divestments Change in Cash Change in Intangibles Change in Intangibles Change in Inventory Change in Inventory Change in Receivables Change in Receivables Depreciation & Amortization (CF)Depreciation & Amortization (CF)Divestments Free Cash Flow Free Cash Flow Gains from Investment Securities Gains from Investment Securities Gains from Sales and Divestitures Gains from Sales and Divestitures Long-Term Debt Issuances Net Cash Flow Net Cash Flow Net Income Non-cash Items Non-cash Items Other Working Capital Changes Other Working Capital Changes Other financing activities Other financing activities Preferred Shares Issued Sales of Property, Plant and Equipment Sales of Property, Plant and Equipment Share-based Compensation Share-based Compensation Shares Issued Short-Term Debt repayments

Daily Values

Growth Metrics

Others

Soleno Therapeutics (SLNO) Net Income (2016 - 2025)

Soleno Therapeutics (SLNO) has disclosed Net Income for 8 consecutive years, with $43.4 million as the latest value for Q4 2025.

For Q4 2025, Net Income changed N/A year-over-year to $43.4 million; the TTM value through Dec 2025 reached $20.9 million, changed N/A, while the annual FY2025 figure was $20.9 million, 111.88% up from the prior year.
Net Income hit $43.4 million in Q4 2025 for Soleno Therapeutics, up from $26.0 million in the prior quarter.
Across five years, Net Income topped out at $43.4 million in Q4 2025 and bottomed at -$43.8 million in Q1 2025.